Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in patients with UC in a real-life population cohort for comparison with the tofacitinib UC clinical trial program. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R, Regueiro, Miguel, Yun, Huifeng, Su, Chinyu, DiBonaventura, Marco, Lawendy, Nervin, Nduaka, Chudy I, Koram, Nana, Cappelleri, Joseph C, Chan, Gary, Modesto, Irene, Lichtenstein, Gary R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376127/
https://www.ncbi.nlm.nih.gov/pubmed/33324993
http://dx.doi.org/10.1093/ibd/izaa289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376127/
https://www.ncbi.nlm.nih.gov/pubmed/33324993
http://dx.doi.org/10.1093/ibd/izaa289

Ejemplares similares